Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.
An FDA report pushes back on claims it's rejecting more drugs, showing first-cycle rejection rates fell from 47% in 2008 to about 27% in 2024.
Anthropic launched a Life Sciences Verification Program, granting select researchers access to AI models Mythos, Opus, and Sonnet, while maintaining biosafety restrictions on high-risk biological ...
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
Michael J. Fox Foundation backs Ariadne Bio's AB-300 & launches $2.5B campaign. SK Bio pays $1.8M for 1ST-104. NICE backs ...
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
Therapeutics prices its Nasdaq IPO, 2026's 21st biotech float, to fund a Phase 2/3 trial of immunology drug ipsoprubart.
Endpoints Executive Editor Drew Armstrong on why picking the 2026 Endpoints 11 was the hardest yet, and what to expect at the Sept. 24 Boston gala.
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
CMS expands ACCESS model, a 10-year Medicare pilot using AI/apps for chronic conditions. 160+ orgs enrolled; 17 health plans ...
Marea and North Immunology take reverse-merger routes to Nasdaq with $225M and $180M financings as I&I dealmaking accelerates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results